Net proceeds from the IPO are expected to total $57.6 million – or $66.7 million if underwriters exercise their full overallotment option of 1 .2 million shares...The immunotherapy firm expects to use net proceeds to fund R&D activities, including a request for orphan drug designation for ADSX-HPV in human papillomavirus-associated diseases, and for working capital and general corporate purposes

Kite Pharma Inc., of Los Angeles, said it closed a $20 million private placement of shares of its Series A preferred stock...Gross proceeds totaled about $35 million, with net proceeds of $32.8 million to fund SFP clinical trials and for other general corporate purposes...The remainder of the net proceeds will be used for continued commercialization of its products, development of its product candidates and for general corporate purposes

The firm also has programs in two big pharma partnerships...Net proceeds of about $86.4 million will be used in part – $19.6 million – to repay in full the company's borrowings under and terminate its credit facility

12, for net proceeds of approximately $9.9 million...Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes

Net proceeds will be used for general corporate purposes...MEI Pharma Inc., of San Diego, priced a public offering of about 2 million shares of common stock at $7.50 apiece, a 9.5 percent discount to Thursday's closing price

Net proceeds totaled $12 million and will be used to fund R&D and clinical trials, acquisition of intellectual property and other purposes...The funds will be used to advance Theraclone's clinical programs and support its I-STAR technology platform.

Net proceeds are expected to support clinical trial costs and acquisition of manufacturing equipment, leasehold improvements and general corporate purposes

Oculus plans to use net proceeds for general corporate purposes, including repaying a portion of certain long-term debt...at the same unit price.

Dezima Pharma BV, of Naarden, the Netherlands, said it raised €14.2 million (US$18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995), and to develop additional earlier-stage dyslipidemia assets...Net proceeds are expected to be about $79.2 million

Tivozanib – an oral, once-daily, VEGF receptor tyrosine kinase inhibitor, partnered by AVEO with Astellas Pharma Inc., of Tokyo – turned up pleasing results in the Phase III trial that compared progression-free survival rates with Nexavar (sorafenib, Onyx Pharmaceuticals Inc.) in kidney cancer, but overall survival (OS) rates caused some eyebrows to rise...Clinical Cancer Research included a paper that suggested the compound, ENMD-2076, acts potently against breast cancer cell lines that lack

MEI Pharma Inc., of San Diego, completed a private placement of common stock and warrants in a financing led by new investors Vivo Ventures and New Leaf Venture Partners...The company intends to use the net proceeds primarily to advance the clinical development of its lead drug candidate, pracinostat, an oral histone deacetylase inhibitor...NeRRe Therapeutics Ltd., of London, raised £11.5 million (US$18.4 million) to develop a portfolio of clinical and preclinical neurokinin receptor antagonists

Net proceeds are expected to total about $44.7 million – or $51.5 million if underwriters exercise in full their overallotment option for 900,000 additional shares – and will be used for commercial launch activities and continued clinical development of the firm's pipeline of extended-release drugs

The net proceeds will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's recently initiated Phase IIb trial of personalized T-cell therapy Tcelna in patients with secondary progressive multiple sclerosis.

About a year earlier, Dutch firm AM-Pharma BV banked €29.2 million (then US$39.8 million) in a Series D round, apparently the largest venture capital financing in Dutch biotechnology thus far...The company planned to switch from a bovine to a recombinant form of its AKI treatment, alkaline phosphatase. (See BioWorld Today, Sept. 14, 2011.) Bunnik, the Netherlands-based AM-Pharma had then gained only preliminary data from two small-scale clinical trials suggesting that bovine alkaline phosphatase

Noting a trend for pharma companies to engage in more collaborations and acquisitions in order to supplement their pipelines with new technology, Lammers said he could envision such an outcome for Mirna...Given the interest of big pharma in microRNA companies, including Mirna, I'm convinced if we have strong human proof-of-concept data in the clinic, most likely pharma will be interested in stepping up to the plate," Lammers said

Net proceeds to the company are about $30 million...Royalty Pharma has invested $25 million under its royalty arrangement with Sunesis, and, in a separate transaction, a syndicate of lenders funded the second tranche of $15 million under their $25 million loan facility with the company

Tranzyme Pharma Inc., of Research Triangle Park, N.C., said it closed a registered direct offering of approximately 3 million shares of its common stock at $3.85 per share for gross proceeds, including an overallotment option, of $11.5 million...The company expects to receive about $10.6 million in net proceeds from the sale of the shares, which will be used for working capital and other general corporate purposes

Net proceeds will be used for general corporate purposes. (See BioWorld Today, July 23, 2012...Net proceeds are expected to support general corporate purposes, including the firm's ongoing commercial activities relating to insomnia drug Silenor (doxepin), for capital expenditures and working capital and for intellectual property protection and enforcement matters

Net proceeds of $26.9 million will be used for general corporate purposes and working capital...Net proceeds will be about $60.7 million and will allow the specialty pharma firm to repay all amounts outstanding under its amended and restated loan and security deal with Oxford Finance LLC and Silicon Valley Bank